• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Court dismisses class action suit against InfuSystem

February 1, 2018 By Sarah Faulkner

InfuSystemThe U.S. District Court for the Central District of California has dismissed a class action lawsuit against InfuSystem (NYSE:INFU) alleging that the company, its ex-CEO and former chief finance executive violated federal securities laws by misleading investors with its financial statements.

The case was brought against InfuSystem in Nov. 2016, after the company and its former CEO, Eric Steen, alongside former CFO Jonathan Foster, informed investors that its financial statements dating back to 2015 couldn’t be relied upon.

InfuSystem said that in those reports, the company had overstated its estimated accounts receivable, which inflated its revenue and pre-tax income figures by $3.3 million, according to the initial complaint.

After the company came forward about the trouble with its financial reporting, its shares fell -38% to close at $1.60 apiece on Nov. 7, 2016.

The shareholder who brought the class action suit against InfuSystem argued that the company violated federal securities laws when it failed to tell investors that it “lacked effective internal control over financial reporting.”

The company filed a motion to dismiss the complaint in June last year and in December, the court dismissed the plaintiff’s first amendment to the complaint. The court later extended the plaintiff’s time to amend the complaint up to Jan. 19, but the plaintiff never filed an amendment. By the end of the month, the court had dismissed the suit.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Hospital Care, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: infusystem

IN CASE YOU MISSED IT

  • Dexcom Q3 earnings top forecasts, as it looks ahead to type 2 coverage
  • Sensonics launches human feasibility study for transmitter-free Eversense CGM
  • Enable Injections, Sanofi obtain approval for on-body myeloma therapy in Japan
  • Abbott sets Libre Duo glucose-ketone sensor US launch for December
  • Sequel Med Tech’s automated twiist pump scores FDA clearance in type 2 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS